ALBI and PALBI Scores and HCC Prognosis

Study Overview
=================
Brief Summary
-----------------
To compare the predictive ability of ALBI and PALBI grades with CTP and MELD scores. To investigate the efficacy of ALBI and PALBI grades for predicting the prognosis of HCC and overall survival among different modalities of treatment.

Official Title
-----------------
Assessment of Prognostic Accuracy of Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades in Hepatocellular Carcinoma Patients According to Different Treatment Modalities

Conditions
-----------------
Hepatocellular Carcinoma (HCC) Prognosis

Intervention / Treatment
-----------------
* Diagnostic Test: ALBI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: • The diagnosis of HCC will be based on the presence of an arterial hypervascular focal lesion > 2 cm with rapid wash-out with a single imaging modality (triphasic computed tomography (CT), or dynamic magnetic resonance imaging (MRI)) or two imaging modalities demonstrating the before mentioned feature for lesions < 2 cm with or without elevated serum alpha-fetoprotein (AFP) levels. Exclusion Criteria: Patients below 18 years old. Patients with pre-existing other malignancies. Patients with pre-existing gall bladder stones, benign strictures, or other biliary diseases. Patients with pre-existing haematologic disorders. Patients with proteinuria. Missed follow-up.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: ALBI|Albumin-Bilirubin and Platelet-Albumin-Bilirubin Grades for prognosis of HCC|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival among HCC patients as assessed by the albumin-bilirubin (ALBI) score | We will compare the ability of ALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores | 2 years | 
| Overall survival among HCC patients as assessed by the platelet-albumin-bilirubin (PALBI) score | We will compare the ability of PALBI score to predict overall survival among HCC patients versus Child Pugh and MELD scores | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival among HCC patients according to treatment modality as assessed by the albumin-bilirubin (ALBI) score | We will compare the ability of ALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care) | 2 years | 
| Overall survival among HCC patients according to treatment modality as assessed by the platelet-albumin-bilirubin (PALBI) | We will compare the ability of PALBI score to predict overall survival among HCC patients stratified according to treatment modality (Surgical resection, local ablation, trans-arterial chemoembolization, sorafenib and best supportive care) | 2 years |